Galera Therapeutics

GRTX49

Penny Stock

$0.07arrow_drop_down0.65%-$0.00

Penny Stock

GRTX49

$0.07

arrow_drop_down0.65%-$0.00

Penny Stock

Performance History

Key Stats
Open	$0.07
Prev. Close	$0.07
EPS	-0.51
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$2.33M
PE Ratio	-

	LOW	HIGH
Day Range	0.07	0.07
52 Week Range	0.05	0.29

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.51

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Galera Therapeutics (GRTX)

Galera Therapeutics Inc (GRTX) is a biotechnology company that focuses on developing novel therapeutics to treat cancer. The company's main product candidate is GC4419, a highly selective small molecule dismutase mimetic that is being investigated for its potential to protect normal tissues from the damaging effects of radiation therapy. Galera's unique approach to addressing radiation-induced toxicity sets it apart from other companies in the field. The company believes that by targeting the underlying mechanisms of radiation damage, it can significantly improve outcomes for cancer patients.

In terms of its stock price history, Galera Therapeutics Inc has experienced significant volatility. The stock initially went public in 2019 at a price of $12 per share. However, it quickly saw a spike in price, reaching a high of $35 per share in early 2020. Since then, the stock has experienced a series of ups and downs, reflecting the uncertainty and risk associated with the biotechnology sector.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. J. Mel Sorensen M.D.
Headquarters: Malvern
Employees: 31
Exchange: NASDAQ

Keep an eye on Galera Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Galera Therapeutics 's (GRTX) price per share?

The current price per share for Galera Therapeutics (GRTX) is $0.08. The stock has seen a price change of -$0 recently, indicating a -0.66% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Galera Therapeutics (GRTX)?

For Galera Therapeutics (GRTX), the 52-week high is $0.29, which is 284.11% from the current price. The 52-week low is $0.05, the current price is 48.04% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Galera Therapeutics (GRTX) a growth stock?

Galera Therapeutics (GRTX) has shown an average price growth of -7.23% over the past three years. It has received a score of 8 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Galera Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Galera Therapeutics (GRTX) stock price performance year to date (YTD)?

As of the latest data, Galera Therapeutics (GRTX) has a year-to-date price change of -50.33%. Over the past month, the stock has experienced a price change of 42.45%. Over the last three months, the change has been 17.24%. Over the past six months, the figure is -59.47%. Looking at a longer horizon, the five-year price change stands at -99.46%.

help

Is Galera Therapeutics (GRTX) a profitable company?

Galera Therapeutics (GRTX) has a net income of -$59.08M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$46.95M. Furthermore, the EBITDA is -$24.81M.

help

What is the market capitalization of Galera Therapeutics (GRTX)?

Galera Therapeutics (GRTX) has a market capitalization of $2.34M. The average daily trading volume is 197.05K, indicating the stock's liquidity and investor engagement.

News

KAILERA THERAPEUTICS

OBESITY

TYPE 2 DIABETES

GLP-1/GIP RECEPTOR DUAL AGONIST

CLINICAL-STAGE THERAPIES

Oct 1, 2024

Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions

EARNINGS RELEASES AND OPERATING RESULTS

May 13, 2024

Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates

MAJOR SHAREHOLDER ANNOUNCEMENTS

May 3, 2024

Galera Adopts Limited Duration Stockholder Rights Agreement